{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:04:40Z","timestamp":1776776680757,"version":"3.51.2"},"reference-count":26,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,3,29]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Hypercalcaemia is a common biochemical complication of malignancy, affecting 20%\u201330% of patients with cancer. Hypercalcaemia of malignancy (HCM) can be driven by multiple different pathological mechanisms, each with variable associations and frequencies across different malignancy types.<\/jats:p>\n                  <jats:p>HCM in indolent lymphomas is exceptionally rare, with only isolated case reports citing its occurrence, and it rarely emerges as the first clinical manifestation. In the case report, we describe a patient with low-grade follicular lymphoma who presented acutely with HCM. This case underscores the importance of identifying the specific mechanism driving HCM to guide timely, targeted treatment and reminds clinicians that, although uncommon, hypercalcaemia can be the initial manifestation of a low-grade lymphoma.<\/jats:p>","DOI":"10.1136\/bcr-2025-271815","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:15:13Z","timestamp":1776773713000},"page":"e271815","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Hypercalcaemia as the first clinical manifestation of follicular lymphoma"],"prefix":"10.1136","volume":"19","author":[{"given":"Louise M","family":"Burrell","sequence":"first","affiliation":[{"name":"General Medicine, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Department of Medicine, The University of Melbourne, Carlton, Victoria, Australia"},{"name":"Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle Aurora Rose","family":"Brugliera","sequence":"additional","affiliation":[{"name":"General Medicine, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew F","family":"Waters","sequence":"additional","affiliation":[{"name":"General Medicine, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026042105150558000_19.4.e271815.1","unstructured":"NSW Government. Hypercalcaemia of malignancy (HCM) . Eviq.org.au. sydney. eviQ; 2005. Available: https:\/\/www.eviq.org.au\/clinical-resources\/oncological-emergencies\/486-hypercalcaemia-of-malignancy-hcm#reference-87e2ff19-987f-4086-a322-85c3de2a9036"},{"key":"2026042105150558000_19.4.e271815.2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1179\/2295333714Y.0000000106","article-title":"Follicular lymphoma presenting with hypercalcaemia: an unusual mechanism of hypercalcaemia","volume":"70","author":"Martens","year":"2015","journal-title":"Acta Clin Belg"},{"key":"2026042105150558000_19.4.e271815.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.18331"},{"key":"2026042105150558000_19.4.e271815.4","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf104","article-title":"Hypercalcemia of Malignancy: Mechanisms and Therapeutic Implications of Concurrently Elevated PTHrP and Calcitriol","volume":"9","author":"Kometas","year":"2025","journal-title":"Journal of the Endocrine Society"},{"key":"2026042105150558000_19.4.e271815.5","doi-asserted-by":"publisher","DOI":"10.4103\/1947-2714.170600"},{"key":"2026042105150558000_19.4.e271815.6","unstructured":"Hypercalcaemia associated with cancer. In: Therapeutic guidelines. Melbourne: Therapeutic Guidelines Limited, 2024. Available: https:\/\/www.tg.org.au"},{"key":"2026042105150558000_19.4.e271815.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2013.08.444","article-title":"Severe hypercalcemia due to large B-cell non-Hodgkin lymphoma","volume":"24","author":"Nave","year":"2013","journal-title":"Eur J Intern Med"},{"key":"2026042105150558000_19.4.e271815.8","unstructured":"Shieh A , Martinez D . Hypercalcaemia of malignancy. BMJ Best Practice 2023. Available: https:\/\/bestpractice.bmj.com\/topics\/en-gb\/1204"},{"key":"2026042105150558000_19.4.e271815.9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Med"},{"key":"2026042105150558000_19.4.e271815.10","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.8.637"},{"key":"2026042105150558000_19.4.e271815.11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042105150558000_19.4.e271815.12","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1210\/clinem\/dgz278","article-title":"Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors","volume":"105","author":"Chukir","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042105150558000_19.4.e271815.13","doi-asserted-by":"crossref","unstructured":"He D , Tavdy T , Tomer Y , et al . SAT191 Primary Hyperparathyroidism With Low-Normal Parathyroid Hormone Levels: Phosphorus Can Be The Key. Journal of the Endocrine Society 2023;7. doi:10.1210\/jendso\/bvad114.488","DOI":"10.1210\/jendso\/bvad114.488"},{"key":"2026042105150558000_19.4.e271815.14","doi-asserted-by":"crossref","DOI":"10.1177\/11795514241290125","article-title":"Primary Hyperparathyroidism With Undetectable Intact Parathyroid Hormone","volume":"17","author":"Song","year":"2024","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2026042105150558000_19.4.e271815.15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00408-015-9826-3","article-title":"Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based Study","volume":"194","author":"Ungprasert","year":"2016","journal-title":"Lung"},{"key":"2026042105150558000_19.4.e271815.16","doi-asserted-by":"crossref","first-page":"2324709613486356","DOI":"10.1177\/2324709613486356","article-title":"Hypercalcemia, Renal Failure, and Skull Lytic Lesions","volume":"1","author":"Alhaj Moustafa","year":"2013","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2026042105150558000_19.4.e271815.17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-256126","article-title":"Hypercalcaemia of malignancy: a case of vitamin-D-mediated hypercalcaemia in lymphoma","volume":"17","author":"Mehta","year":"2024","journal-title":"BMJ Case Rep"},{"key":"2026042105150558000_19.4.e271815.18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2141.1994.tb06752.x","article-title":"Hypercalcaemia in B cell chronic lymphocytic leukaemia","volume":"87","author":"Fain","year":"1994","journal-title":"Br J Haematol"},{"key":"2026042105150558000_19.4.e271815.19","first-page":"1","article-title":"Transformation of Follicular Lymphoma to Double Hit B-Cell Lymphoma Causing Hypercalcemia in a 69-Year-Old Female: A Case Report and Review of the Literature","volume":"2014","author":"Kapur","year":"2014","journal-title":"Case Rep Hematol"},{"key":"2026042105150558000_19.4.e271815.20","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1211::AID-CNCR21>3.0.CO;2-1"},{"key":"2026042105150558000_19.4.e271815.21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1056\/NEJMx220006","article-title":"Cancer-Associated Hypercalcemia","volume":"387","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042105150558000_19.4.e271815.22","first-page":"496","article-title":"Hypercalcemia of Malignancy","volume":"9","author":"Feldenzer","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"2026042105150558000_19.4.e271815.23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7861\/clinmed.2023-0227","article-title":"Treatment of hypercalcaemia of malignancy in adults","volume":"23","author":"Mc Donald","year":"2023","journal-title":"Clin Med (Northfield)"},{"key":"2026042105150558000_19.4.e271815.24","unstructured":"Australian Medicines Handbook Pty Ltd . Calcitonin salmon. Adelaide: Australian Medicines Handbook Pty Ltd. 2025. Available: https:\/\/amhonline.amh.net.au\/"},{"key":"2026042105150558000_19.4.e271815.25","doi-asserted-by":"crossref","DOI":"10.20945\/2359-4292-2024-0035","article-title":"Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review","volume":"68","author":"Schmitt","year":"2024","journal-title":"Arch Endocrinol Metab"},{"key":"2026042105150558000_19.4.e271815.26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:15:18Z","timestamp":1776773718000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bcr-2025-271815"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271815","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}